Skip to content

Molecular Mechanism of circFANCB in Ascites-Derived Exosomes Promoting Gastric Cancer Metastasis via the miR-454-3p/CEACAM5 Pathway

Molecular Mechanism of circFANCB in Ascites-Derived Exosomes Promoting Gastric Cancer Metastasis via the miR-454-3p/CEACAM5 Pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114490
Enrollment
Unknown
Registered
2025-12-12
Start date
2026-01-07
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Non-cancerous ascites group:None
Cancerous ascites group:None

Sponsors

Ningbo Beilun People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for gastric cancer patients: (1) Patients aged 18–65 years; (2) Patients clinically and pathologically diagnosed with gastric cancer (GC), accompanied by ascites; (3) Patients who have not received any radiotherapy or chemotherapy before surgery; (4) Patients with complete clinical and pathological data (including age, sex, tumor differentiation, TNM staging, lymph node staging, etc.); 2. Inclusion criteria for liver cirrhosis patients: (1) Patients aged 18–65 years; (2) Patients clinically and pathologically diagnosed with primary liver cirrhosis via liver biopsy, accompanied by ascites; (3) Patients with complete clinical data (including age, sex, etc.).

Exclusion criteria

Exclusion criteria: 1. Severe organic or functional diseases of the kidney, heart, brain, or other organs; 2. Pregnant or breastfeeding women; 3. Having other primary malignant tumors; 4. Mental disorders, unable or unwilling to cooperate with follow-up and re-examination; 5. Currently participating in any other treatment clinical trials.

Design outcomes

Primary

MeasureTime frame
Expression of CEACAM5;Expression of E-cadherin;Expression of Vimentin;Expression of E-cadherin;

Countries

China

Contacts

Public ContactHaifeng Wang

Ningbo Beilun People’s Hospital

309692852@qq.com+86 574 86776610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026